Global Diabetic Nephropathy Market 2014-2018


◆タイトル:Global Diabetic Nephropathy Market 2014-2018
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥305,200見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Diabetic Nephropathy
Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease. Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control.
TechNavio’s analysts forecast the Global Diabetic Nephropathy market will grow at a CAGR of 5.19 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market.
TechNavio’s report, the Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
Key Vendors
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corp.
• Novartis AG
• Sanofi S.A.
Other Prominent Vendors

• AbbVie Inc.
• Ampio Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Bayer AG
• ChemoCentryx Inc.
• Eli Lilly and Co.
• GenKyoTex S.A.
• Glycadia Pharmaceuticals Inc.
• IMMD Inc.
• Mesoblast Ltd.
• NephroGenex Inc.
• Novo Nordisk A/S
• NOXXON Pharma AG
• OncoImmune Inc.
• Pfizer Inc.
• PhytoHealth Corp.
• Questcor Pharmaceuticals Inc.
• Reata Pharmaceuticals Inc.
Key Market Driver
• Increase in Prevalence of Diabetes.
• For a full, detailed list, view our report.
Key Market Challenge
• Increasing Number of Patent Expirations.
• For a full, detailed list, view our report.
Key Market Trend
• Increase in Awareness of Diabetic Nephropathy Drugs.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
More Information about Diabetic Nephropathy


01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 DN Market in the US
06.3.1 Market Size and Forecast
06.4 DN Market in Europe
06.4.1 Market Size and Forecast
06.5 Five Forces Analysis
07. Pipeline Snapshot
08. Rate of Incidence and Prevalence
09. Geographical Segmentation
09.1 DN Market in the Americas
09.1.1 Market Size and Forecast
09.2 DN Market in the EMEA Region
09.2.1 Market Size and Forecast
09.3 DN Market in the APAC Region
09.3.1 Market Size and Forecast
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2013
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Merck & Co. Inc.
18.1.1 Business Overview
18.1.2 Business Segmentation
18.1.3 Key Information
18.1.4 SWOT Analysis
18.2 Mitsubishi Tanabe Pharma Corp.
18.2.1 Business Overview
18.2.2 Key Information
18.2.3 SWOT Analysis
18.3 Novartis AG
18.3.1 Business Overview
18.3.2 Business Segmentation
18.3.3 Key Information
18.3.4 SWOT Analysis
18.4 Sanofi S.A.
18.4.1 Business Overview
18.4.2 Business Segmentation
18.4.3 Key Information
18.4.4 SWOT Analysis
19. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global DN Market 2013-2018 (US$ billion)
Exhibit 3: DN Market in the US 2013-2018 (US$ billion)
Exhibit 4: DN Market in Europe 2013-2018 (US$ billion)
Exhibit 5: Global DN Market by Geographical Segmentation 2013
Exhibit 6: DN Market in the Americas 2013-2018 (US$ billion)
Exhibit 7: DN Market in the EMEA Region 2013-2018 (US$ billion)
Exhibit 8: DN Market in the APAC Region (US$ billion)
Exhibit 9: Global DN Market by Geographical Segmentation
Exhibit 10: Business Segmentation of Merck & Co. Inc.
Exhibit 11: Business Segmentation of Novartis AG
Exhibit 12: Business Segmentation of Sanofi S.A.


Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Sanofi S.A., AbbVie Inc., Ampio Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, ChemoCentryx Inc.. Eli Lilly and Co., GenKyoTex S.A., Glycadia Pharmaceuticals Inc., IMMD Inc., Mesoblast Ltd., NephroGenex Inc., Novo Nordisk A/S, NOXXON Pharma AG, OncoImmune Inc., Pfizer Inc., PhytoHealth Corp., Questcor Pharmaceuticals Inc., Reata Pharmaceuticals Inc.



★調査レポート[世界の糖尿病腎症治療市場動向(2014-2018)] (Global Diabetic Nephropathy Market 2014-2018 / IRTNTR3393)販売に関する免責事項
[世界の糖尿病腎症治療市場動向(2014-2018)] (Global Diabetic Nephropathy Market 2014-2018 / IRTNTR3393)についてEメールでお問い合わせ